Investors
Alta Partners
was founded in 1996 as a successor to Burr, Egan, Deleage & Co. (BEDCO), a premier venture capital firm established in 1979. Alta Partners builds on the BEDCO legacy combining capital and experience with exceptional entrepreneurial talent to achieve investing success. Alta Partners has invested in and helped grow over 125 companies in telecommunications, networking, software, electronic commerce, biotechnology and medical devices.
Crédit Agricole Private Equity
is an AMF-accredited asset management subsidiary of Credit Agricole S.A., specialising in private equity investment in non-listed companies. A reference within the private equity market, it has a team of 40 investors operating in several areas (LBO/Expansion, Venture Capital, Secondary Market, Mezzanine, Renewable Energies, PPP Infrastructure, liquidity solutions, etc.), manages €1.5 billion through venture and innovation funds. Crédit Agricole Private Equity provides advice and support for business managers implementing growth plans.
Dansk Innovationsinvestering P/S
is a 50:50 venture capital partnership between the Danish Growth Fund and A/S Dansk Erhvervsinvestering, one of the oldest venture capital companies in Denmark. Managed by Dansk Erhvervsinvestering, Dansk Innovationsinvestering invests primarily in early stage biotech and health care ventures.
GIMV
is a listed European investment company with more than 28 years of experience in private equity and venture capital. Gimv’s local buyout teams target small to medium sized companies in Belgium, the Netherlands, France and Germany. In technology businesses Gimv provides venture capital to help startups expand or internationalise. Venture capital investments are made in Life Sciences, Technology and Cleantech.
As an active partner and coach, Gimv supplies not only financing, but also know-how and experience to the companies in its portfolio, reinforcing and supporting their growth.
Global Life Science Ventures (GLSV)
is an independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.
Index Ventures
is a pan-European venture capital fund investing in the fields of life science and information technology. Previous investments include Addex Pharmaceuticals, BioXell, Cellzome, Genmab, Structural Genomix, Ingenium and ParAllele Bioscience. The firm’s advisory board comprises of world-known experts and senior executives from top-tier corporations.
www.indexventures.com
Johnson & Johnson Development Corporation (JJDC)
is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies.
LD Pensions
is among the largest institutional investors in Denmark with a capital of more than USD 8 billion, and is primarily investing in bonds and equities, including private equity. Investments are made in public companies but also in private companies whose activities demonstrate viability and business potential. The investments are made on a long-term basis and are very selective. LD Pensions has among others invested in ACADIA Pharmaceuticals, Inc., Pharmexa A/S, NeuroSearch A/S, Bavarian Nordic Research Institute A/S, Genmab A/S, Zealand Pharma A/S, NsGene A/S, NatImmune A/S, Santaris A/S, Symphogen A/S, and Exiqon A/S.
Novo A/S
is a private company, wholly owned by the Novo Nordisk Foundation. Novo A/S provides venture capital and expertise for development stage companies with a pioneering concept within life-sciences. Novo A/S holds significant shareholdings in Novo Nordisk A/S and Novozymes A/S.
Scottish Widows Investment Partnership (SWIP)
is one of the largest asset management companies in the UK. In total, it manages £94.9bn worth of funds, which are invested in all major asset classes, including domestic and overseas equities, property, bonds and cash. SWIP currently manages around 2% of the UK equity market and is one of the UK’s leading bond and property investors. SWIP is an independent asset manager which runs a number of life assurance, pension and investment funds for Scottish Widows and its parent company Lloyds TSB. It also manages a diverse range of specialist funds for other UK and international clients, including large pension schemes, charities and local governments.
Sofinnova Partners
is an independent venture capital company based in Paris with special relations with Sofinnova Ventures, our sister firm based in San Francisco. Sofinnova invest primarily in companies in start-ups and early-stage companies with ambitious projects in information technologies and life sciences, in France and in other European countries; a limited portion of investments is made in the US with a preference for companies capable of attracting European investors. Sofinnova’s team usually invests as lead or co-lead investor in first and second rounds in collaboration with leading European, US and Asian venture capital funds, especially in the UK, Switzerland, Germany, Scandinavia, Belgium and Luxembourg.
SR One Limited
is GlaxoSmithKline's independent corporate healthcare venture fund. The Fund's mission is to invest globally in emerging biotech companies that are focused on drug discovery, delivery or development and have the potential to make products that will offer a dramatic benefit to patients. SR One is committed to making investments that can provide attractive returns and significant strategic value. Since its founding in 1985, SR One has invested more than USD 500 million in more than 120 companies located in the US and Europe. Today, there are about 30 private and public companies in the SR One portfolio. The SR One team includes six investment professionals based in the US and Europe and has experience that spans venture-capital investing, business development, Wall Street, pharmaceutical R&D, medical practice, and business start-ups.
The LODH Immunology Fund
is a Swiss open-ended mutual fund managed by Lombard Odier Darier Hentsch & Cie, a Swiss private bank. Approximately 20% of the assets of the fund are invested in privately held biotech companies.
Baker/Tisch Investments
refers to a family of private investment funds focused on the life sciences industry. Located in New York City, these funds provide long-term equity capital to public and private companies, and currently manage investments in over 40 life sciences companies.
BioMedinvest AG
is a healthcare-dedicated venture capital fund based in Switzerland, providing private equity financing to early- to mid-stage companies in Switzerland and neighbouring regions (Alpine Rim). BioMedInvest currently invests out of Fund I, which has a size of CHF 100 million and was closed in 2003. BioMedInvest's investment strategy allows for investments in start-up companies looking for first round funding through to later-stage or spin-off companies focused on product development in the biotechnology, emerging pharmaceuticals, healthcare and medical technology sectors.